A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. ・The company retired its senior loan ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Eli Lilly and Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's closely-watched Alzehimer's trials - which failed on Monday to show it ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.

The oral version of Wegovy is proving to have similar efficacy, safety, and tolerability when compared to its injectable version. Clinical trial data suggest that Novo Nordisk's oral Wegovy is ahead ...

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster medications.

In a move that could significantly enhance its obesity treatment portfolio, Novo Nordisk has submitted a 7.2 mg formulation of Wegovy for regulatory approval. The submission, accepted for accelerated ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

The Trump administration is expected to announce deals with Eli Lilly and Novo Nordisk to cut prices of some weight loss drugs.